$HALB Halberd Corporation Alzheimer's Disease Trea
Post# of 98043
(Total Views: 90)
Posted On: 08/30/2021 1:39:41 PM
$HALB Halberd Corporation Alzheimer's Disease Treatment Tests Yield Outstanding Results
https://www.accesswire.com/661905/halberd-cor...ng-results
JACKSON CENTER, PA / ACCESSWIRE / August 30, 2021 / Halberd Corp. (OTC PINK:HALB) provided an update on its Alzheimer's Disease eradication experimentation being conducted at Youngstown State University (YSU) and Arizona State University (ASU). Following standard scientific methodology, Halberd conducted two rounds of experimentation on Phosphorylated Tau, and the results were so astounding that the researchers want to conduct further replication tests prior to publication in scientific articles.
Bodily fluids treated with nanoparticles conjoined to specific antibodies attract and adhere to target disease antigens. These conjoined target antigens are subjected to laser emissive energy and to radio frequency waves in separate experiments. Halberd's initial target disease antigen, Phosphorylated Tau, is the primary building block of neurofibrillary tangles associated with the onset and progression of Alzheimer's Disease and other neurodegenerative diseases.
William A. Hartman, Halberd Corporation's Chairman, President & CEO, stated. "Once the replication testing is completed, our researchers will commence writing scientific articles on the technology and results. These tests and the scientific documents should be completed within the next several weeks. Testing on the other antigens associated with Alzheimer's Disease will commence at that time."
"Halberd's previous testing on E. Coli also yielded stunningly positive results, which are also being replicated prior to publication," Hartman concluded.
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
https://www.accesswire.com/661905/halberd-cor...ng-results
JACKSON CENTER, PA / ACCESSWIRE / August 30, 2021 / Halberd Corp. (OTC PINK:HALB) provided an update on its Alzheimer's Disease eradication experimentation being conducted at Youngstown State University (YSU) and Arizona State University (ASU). Following standard scientific methodology, Halberd conducted two rounds of experimentation on Phosphorylated Tau, and the results were so astounding that the researchers want to conduct further replication tests prior to publication in scientific articles.
Bodily fluids treated with nanoparticles conjoined to specific antibodies attract and adhere to target disease antigens. These conjoined target antigens are subjected to laser emissive energy and to radio frequency waves in separate experiments. Halberd's initial target disease antigen, Phosphorylated Tau, is the primary building block of neurofibrillary tangles associated with the onset and progression of Alzheimer's Disease and other neurodegenerative diseases.
William A. Hartman, Halberd Corporation's Chairman, President & CEO, stated. "Once the replication testing is completed, our researchers will commence writing scientific articles on the technology and results. These tests and the scientific documents should be completed within the next several weeks. Testing on the other antigens associated with Alzheimer's Disease will commence at that time."
"Halberd's previous testing on E. Coli also yielded stunningly positive results, which are also being replicated prior to publication," Hartman concluded.
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
(0)
(0)Scroll down for more posts ▼